Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26206075 | 0.86 | ADRB2 (0.37) | EPHX2PDE3BPDE3AP2RY12ITGB3 | |
| SCHEMBL26206388 | 0.85 | MAPT (0.50) | ITGB3ITGA2B | |
| SCHEMBL19866247 | 0.82 | TSHR (0.50) | — | |
| SCHEMBL26206085 | 0.80 | ADRB2 (0.43) | ADRB2ADRB1 | |
| SCHEMBL22526120 | 0.78 | REN (0.40) | EPHX2 | |
| SCHEMBL24602631 | 0.77 | ALDH1A1 (0.48) | EPHX2PDE3BPDE3AP2RY12HPGD | |
| SCHEMBL28275792 | 0.76 | LOXL2 (0.51) | EPHX2PDE3BPDE3AP2RY12HPGD | |
| SCHEMBL9689657 | 0.76 | MAOB (0.48) | EPHX2PDE3BPDE3AP2RY12HPGD | |
| SCHEMBL27265750 | 0.76 | ALDH1A1 (0.47) | EPHX2PDE3BPDE3AP2RY12HPGD | |
| SCHEMBL22921868 | 0.75 | TSHR (0.58) | EPHX2CYP4F2CYP4A11CYP4Z1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | EPHX2 1511/4885PDE3B 934/4885PDE3A 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.